Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 Agosto 2023 - 6:00PM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for rare and ultra-rare diseases, today reported the
grant of 42,840 restricted stock units of the company’s common
stock to 18 newly hired non-executive officers of the company. The
awards were approved by the compensation committee of the company’s
board of directors and granted under the Ultragenyx Employment
Inducement Plan, with a grant date of August 16, 2023, as an
inducement material to the new employees entering into employment
with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25% of the
underlying shares vesting on each anniversary of the grant date,
subject to the employee being continuously employed by the company
as of such vesting dates.
About Ultragenyx Pharmaceutical Inc.Ultragenyx
is a biopharmaceutical company committed to bringing novel products
to patients for the treatment of serious rare and ultra-rare
genetic diseases. The company has built a diverse portfolio of
approved therapies and product candidates aimed at addressing
diseases with high unmet medical need and clear biology for
treatment, for which there are typically no approved therapies
treating the underlying disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at: www.ultragenyx.com.
Contact Ultragenyx Investors & MediaJoshua Higa(415)
475-6370
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024